PI3K, short for phosphoinositide 3-kinase, is a family of enzymes that act as a central relay station inside your cells, translating signals from the outside world into instructions for growth, metabolism, and survival. Discovered roughly thirty years ago as a lipid kinase linked to cancer-promoting proteins, PI3K has since turned out to be involved in an enormous range of biological processes, from how your body responds to insulin to how immune cells fight infection to how tumors feed themselves.1PubMed. PIK3CA in cancer: The past 30 years Its outsized role in both normal physiology and disease has made it one of the most intensely studied drug targets in oncology, with real drugs now on the market and a long list of complications that come with trying to shut down something your healthy cells also need.
What PI3K Actually Does in a Healthy Cell
Think of PI3K as a molecular switch that gets flipped whenever a cell receives certain “go” signals. Those signals come from growth factor receptors on the cell surface, G protein-coupled receptors, and small signaling proteins in the Ras family.2Cell. What Is PI3K? A Key Pathway in Health and Cancer When a hormone, growth factor, or nutrient binds to its receptor on the outside of the cell, the receptor changes shape and activates PI3K on the inner side of the cell membrane. Once switched on, PI3K modifies a membrane lipid called PIP2 by adding a phosphate group, converting it into PIP3. That one chemical change creates a landing pad on the membrane for a protein called AKT, which then gets activated and relays the signal further into the cell.3PubMed Central. HER2/PI3K/AKT pathway in HER2-positive breast cancer: A review
The downstream effects are sweeping. AKT activation tells the cell to take up more glucose, ramp up protein production, grow larger, and divide. One of the key downstream targets is mTOR, a protein that essentially coordinates the cell’s building program, deciding when to make new proteins and lipids.4PubMed Central. Insulin-PI3K signalling: an evolutionarily insulated metabolic driver of cancer In healthy tissue, this cascade is precisely calibrated. Your muscle cells, for instance, use PI3K signaling after a meal: insulin binds to its receptor, PI3K activates AKT, and AKT triggers the movement of glucose transporters to the cell surface so that sugar can be pulled out of the bloodstream.5IntechOpen. Role of PI3K/AKT Pathway in Insulin-Mediated Glucose Uptake Without this chain of events, your cells would starve in a sea of glucose.
The Brake Pedal Called PTEN
A signaling pathway this powerful needs a strong off switch, and that is the job of PTEN, a tumor suppressor often described as the major brake on PI3K signaling. PTEN works by doing the exact opposite of PI3K: it strips the phosphate group off PIP3, converting it back to PIP2 and effectively pulling the rug out from under AKT.6PubMed Central. PTEN Tumor Suppressor Network in PI3K-Akt Pathway Control As long as PI3K and PTEN are in balance, the cell grows when it should and stops when it should. When PTEN is lost or silenced, PIP3 accumulates unchecked, AKT stays chronically active, and the cell receives a constant green light for growth and survival. PTEN is one of the most commonly disrupted tumor suppressors across human cancers, and its loss is a major reason why PI3K pathway activity ends up so high in tumors even when PI3K itself has not mutated.7PubMed Central. PTEN and the PI3-kinase pathway in cancer
How PI3K Goes Wrong in Cancer
The PI3K/AKT pathway is one of the most frequently overactivated signaling routes in human tumors.8PubMed Central. The Pathogenic Role of PI3K/AKT Pathway in Cancer Onset and Drug Resistance: An Updated Review There are two main ways this happens. The first is a gain-of-function mutation in PIK3CA, the gene encoding the p110α catalytic subunit of PI3K. A mutation here produces a version of the enzyme that is permanently turned on, or at least far too easy to turn on, so cells grow and divide without needing as much external stimulation. The second route is loss of PTEN, which removes the brake as described above. Many tumors use one of these two strategies, and occasionally both at once.
In breast cancer, PIK3CA mutations are among the most common genetic changes. They appear in roughly a quarter to over a third of cases, depending on the subtype, and are especially frequent in hormone receptor-positive and HER2-positive tumors.9PubMed Central. PIK3CA mutations in breast cancer: reconciling findings from preclinical and clinical data 10PubMed Central. PIK3CA mutations associated with gene signature of low mTORC1 signaling and better outcomes in estrogen receptor-positive breast cancer But PIK3CA mutations are not limited to the breast. They show up across a wide range of cancer types, including endometrial, ovarian, colorectal, and head and neck cancers, making PI3K one of the most broadly relevant oncogenic pathways in human biology.
Melanoma provides an interesting example of the PTEN-loss route. PTEN is rarely deleted outright in melanoma, and intragenic mutations are uncommon. Instead, the gene is often silenced epigenetically, meaning the DNA sequence is intact but chemical modifications prevent the gene from being read.11PubMed Central. Epigenetic PTEN silencing in malignant melanomas without PTEN mutation 12PubMed. Epigenetic silencing of the PTEN gene in melanoma The result is the same: the PTEN protein disappears and PI3K signaling runs hot. This matters for diagnosis and treatment because standard genetic sequencing would miss this kind of inactivation entirely.
The Metabolic Rewiring That Feeds Tumors
Cancer cells are famously greedy for glucose, and PI3K is a big part of why. When the pathway is chronically active, it pushes cells to increase glucose uptake through glucose transporters and to favor glycolysis, the rapid, less efficient way of burning sugar that cancer cells tend to rely on even when oxygen is plentiful.13PubMed Central. Regulation of PI3K signaling in cancer metabolism and PI3K-targeting therapy Active PI3K/AKT signaling also stimulates lipid production and amino acid metabolism, giving tumor cells the raw building materials for new membranes, proteins, and DNA.14PubMed. PI3K signaling-regulated metabolic reprogramming: From mechanism to application
Recent research in ovarian cancer illustrates how this plays out in specific tumors. Elevated expression of certain regulatory proteins was found to activate PI3K/AKT signaling and increase the expression of glycolytic enzymes, boosting glucose uptake, lactate production, and energy generation. Blocking AKT or glycolysis reversed these effects, confirming that the metabolic rewiring depends on PI3K pathway activity.15PubMed Central. ZNF280A and ACRV1 enhance aerobic glycolysis and drive ovarian cancer progression via the PI3K/AKT signaling pathway This tight link between PI3K and tumor metabolism is one reason why PI3K inhibitors do more than just slow cell division. They can also starve tumor cells of their preferred fuel.
PI3K and Cell Movement
Growth and metabolism are not the only things PI3K controls. The pathway also plays a direct role in cell migration, which has obvious implications for how cancers spread. PI3K helps organize the cell’s internal skeleton by activating small GTPases from the Rho and Arf families, which reshape the cytoskeleton so a cell can extend protrusions, grip a surface, and pull itself forward.16PubMed Central. What Is PI3K? A Key Pathway in Health and Cancer – Section: PI3K and Cytoskeletal Rearrangements In normal tissue, this is essential for wound healing and immune cell migration. In cancer, the same machinery drives invasion and metastasis, allowing tumor cells to leave the primary site and colonize distant organs. Overactivation of the PI3K/AKT pathway enhances this migratory capacity and promotes the epithelial-to-mesenchymal transition, a process in which tumor cells become more mobile and resistant to death.
Drugs That Target PI3K
Given how central PI3K is to cancer biology, pharmaceutical companies have spent years trying to develop drugs that block it. The first generation of PI3K inhibitors were pan-PI3K or dual PI3K/mTOR inhibitors, meaning they blocked multiple versions of PI3K at once (or PI3K and mTOR together). These showed moderate clinical success but caused broad side effects because they suppressed PI3K signaling across healthy tissues as well as tumors.17PubMed Central. CBF-Beta Mitigates PI3K-Alpha-Specific Inhibitor Killing through PIM1 in PIK3CA-Mutant Gastric Cancer The field then shifted toward isoform-specific inhibitors, drugs designed to block just one version of PI3K, like the p110α isoform that is most commonly mutated in solid tumors.
The most prominent example is alpelisib, which targets PI3Kα specifically and was tested in combination with the hormone therapy fulvestrant for women with PIK3CA-mutated, hormone receptor-positive advanced breast cancer. In a major trial, the combination nearly doubled median progression-free survival compared to fulvestrant alone: about 11 months versus roughly 5.7 months.18PubMed. Alpelisib for PIK3CA-Mutated, Hormone Receptor-Positive Advanced Breast Cancer That result led to regulatory approval and made alpelisib the first PI3K inhibitor approved for solid tumors based on a genetic biomarker, meaning patients are selected for treatment based on whether their tumor carries a PIK3CA mutation.
Side effects remain a significant challenge. Because PI3Kα also handles insulin signaling in normal tissues, blocking it tends to raise blood sugar. Hyperglycemia is one of the most common toxicities, alongside skin rash, mouth sores, diarrhea, nausea, and fatigue.19PubMed Central. Management of toxicity to isoform α-specific PI3K inhibitors These side effects are usually reversible with dose adjustments or supportive medications, but they can limit how long patients stay on therapy and underscore the fundamental tension in targeting a pathway that healthy cells rely on. Newer compounds are under development that aim to block only the mutant form of PI3Kα while leaving the normal protein relatively untouched, potentially widening the therapeutic window.
Why Tumors Fight Back
Even when PI3K inhibitors work initially, tumors often develop resistance. One well-characterized mechanism involves a feedback loop with HER3, a receptor that can reactivate PI3K signaling from upstream. Normally, active PI3K/AKT keeps HER3 expression low by phosphorylating a protein called FOXO3a, which sequesters it away from the HER3 gene. When a drug shuts down PI3K or AKT, FOXO3a becomes unphosphorylated, migrates into the nucleus, and turns HER3 expression back up. The newly abundant HER3 then reactivates PI3K signaling, essentially routing around the drug.20AACR Journals. What a Tangled Web We Weave: Emerging Resistance Mechanisms to Inhibition of the Phosphoinositide 3-Kinase Pathway
This is not the only escape route. Tumors can also activate parallel signaling pathways that bypass PI3K altogether, or amplify downstream components to keep the growth signal flowing even when PI3K itself is blocked. Researchers have found, for instance, that loss of certain regulatory proteins or upregulation of survival genes like PIM1 can blunt the effectiveness of PI3Kα-specific inhibitors in gastric cancer.17PubMed Central. CBF-Beta Mitigates PI3K-Alpha-Specific Inhibitor Killing through PIM1 in PIK3CA-Mutant Gastric Cancer The upshot is that single-agent PI3K therapy often fails over time, which has driven interest in combination approaches.
One promising strategy pairs PI3K pathway inhibitors with CDK4/6 inhibitors, a class of drugs that block cell-cycle progression and are already standard of care in hormone receptor-positive breast cancer. When tumors become resistant to CDK4/6 inhibitors, they often show increased PI3K/mTOR signaling, suggesting the two pathways compensate for each other. Preclinical evidence supports using both drug classes together, or sequentially, to delay or overcome resistance.21PubMed Central. Targeting activated PI3K/mTOR signaling overcomes acquired resistance to CDK4/6-based therapies in preclinical models of hormone receptor-positive breast cancer Clinical trials are testing various versions of this idea, and the principle extends beyond breast cancer to any setting where PI3K activation is a resistance mechanism.
PI3K Beyond Cancer
Insulin Resistance and Metabolic Disease
Because PI3K is the central relay in insulin signaling, problems with this pathway contribute directly to metabolic disease. When PI3K/AKT signaling is impaired in muscle, fat, or liver tissue, those tissues stop responding properly to insulin, a condition known as insulin resistance. This drives blood sugar up and contributes to the development of obesity and type 2 diabetes. The relationship is bidirectional: insulin resistance further damages PI3K/AKT signaling, creating a cycle that is hard to break.22PubMed Central. The PI3K/AKT pathway in obesity and type 2 diabetes This overlap is also why PI3K-targeting cancer drugs raise blood sugar as a side effect. They are, in a very real sense, inducing a temporary state of insulin resistance on purpose.
Immune Function and Autoimmune Disease
Two members of the PI3K family, PI3Kδ and PI3Kγ, are heavily expressed in immune cells and play specialized roles in immune activation and inflammation. Blocking these isoforms in mice reduces susceptibility to autoimmune and inflammatory conditions, and there has been active interest in developing PI3Kδ and PI3Kγ inhibitors for diseases like rheumatoid arthritis and lupus.23PubMed Central. The Therapeutic Potential for PI3K Inhibitors in Autoimmune Rheumatic Diseases 24PubMed Central. PI3K inhibitors in inflammation, autoimmunity and cancer In fact, idelalisib, a PI3Kδ inhibitor, was approved for certain blood cancers partly because it exploits the dependence of B-cell malignancies on PI3Kδ signaling. The immune connection also means that PI3K inhibitors used in cancer can suppress immune function as an unintended consequence, occasionally leading to opportunistic infections in treated patients.
PI3K in the Brain and in Aging
The pathway’s reach extends into the nervous system. PI3K signaling influences how neurons establish polarity, how their branches grow, and how synaptic connections strengthen or weaken over time.25PubMed Central. Phosphatase and tensin homolog, deleted on chromosome 10 deficiency in brain causes defects in synaptic structure, transmission and plasticity, and myelination abnormalities When PTEN is lost specifically in brain tissue, for instance, the resulting overactivation of PI3K leads to defects in synaptic transmission, plasticity, and the insulation of nerve fibers. These findings have implications for neurodevelopmental disorders; PTEN mutations are among the genetic risk factors for autism spectrum disorder, possibly through their effect on PI3K-driven overgrowth of neural tissue.
Aging research has uncovered a counterintuitive twist. In organisms from yeast to mammals, modestly reducing PI3K/AKT/mTOR signaling extends healthy lifespan.26Experimental Gerontology. Review PI3-kinase/Akt/mTOR signaling: Impaired on/off switches in aging, cognitive decline and Alzheimer’s disease The key word is “modestly.” Completely shutting the pathway down would be catastrophic. But dialing it back, much as calorie restriction does naturally, appears to slow aging processes and improve resilience. The insulin/IGF-1 signaling pathway, of which PI3K is a core component, was in fact the first nutrient-sensing pathway shown to regulate aging across species.27PubMed. Insulin/insulin-like growth factor-1 signalling (IIS) based regulation of lifespan across species This creates an interesting paradox: the same pathway that drives cancer when overactive may accelerate aging when running at full steam in normal tissues.
In Alzheimer’s disease, the picture gets more complicated. Exercise has been shown to boost PI3K/AKT signaling in the brain along with BDNF, a key nerve growth factor, and this activation appears to protect neurons from the toxic effects of amyloid-beta plaques in mouse models.28PubMed Central. Neuroprotective effects of treadmill exercise on BDNF and PI3-K/Akt signaling pathway in the cortex of transgenic mice model of Alzheimer’s disease So while chronically high PI3K activity may accelerate aging in the long run, acute boosts in the right context seem to protect the brain. The resolution probably lies in timing and tissue specificity: what the brain needs from PI3K during a bout of exercise is different from what a tumor gets from having the pathway permanently stuck in the “on” position.
Why There Are Multiple PI3Ks
One thing that often confuses people encountering this topic for the first time is that “PI3K” is not one protein but a family. There are four class I isoforms, each encoded by a different gene and expressed in different patterns across tissues. The α isoform (p110α) is the one most commonly mutated in solid tumors. The β isoform (p110β) has unusual properties, including activation by a different set of upstream signals, and plays a role in platelet function and certain PTEN-loss-driven cancers. The δ and γ isoforms are concentrated in immune cells, which is why they are targets for blood cancers and autoimmune conditions.2Cell. What Is PI3K? A Key Pathway in Health and Cancer
This isoform diversity is both a challenge and an opportunity for drug development. It is a challenge because a drug designed to block one isoform can accidentally hit another, causing side effects in tissues that were never the intended target. The early pan-PI3K inhibitors ran into exactly this problem. But it is an opportunity because a selective enough drug can, in theory, hit the disease-driving isoform while leaving the others alone. Alpelisib’s selective targeting of p110α is the best clinical example so far, though even it causes metabolic side effects because healthy tissues also use p110α for insulin signaling. The next generation of compounds aims for mutant-selective inhibition, blocking only the cancer-specific altered form of p110α, which would represent a genuine leap in precision if it works in patients.
Dual PI3K/mTOR inhibitors remain under investigation as well, with newer molecules designed to overcome the solubility and metabolic stability problems that limited earlier compounds. Some have shown promising activity in laboratory models of drug-resistant leukemia, including cell lines that carry multidrug-resistance machinery.29PubMed Central. New Dual Pan-PI3K/mTOR Inhibitor: Design, Synthesis, Cytotoxic Action, Permeation, Metabolic Stability, and In Silico Protein-Ligand Interaction Whether these newer agents will translate into better patient outcomes is an open question, but the pace of chemical innovation in this space has not slowed down after three decades.